| Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial EM Swisher, KK Lin, AM Oza, CL Scott, H Giordano, J Sun, GE Konecny, ... The lancet oncology 18 (1), 75-87, 2017 | 1193 | 2017 |
| Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer V Makker, N Colombo, A Casado Herraez New England Journal of Medicine 386 (5), 437-448, 2022 | 562 | 2022 |
| Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial J Trigo, V Subbiah, B Besse, V Moreno, R López, MA Sala, S Peters, ... The lancet oncology 21 (5), 645-654, 2020 | 371 | 2020 |
| Dostarlimab for primary advanced or recurrent endometrial cancer MR Mirza, DM Chase, BM Slomovitz, R dePont Christensen, Z Novák, ... New England Journal of Medicine 388 (23), 2145-2158, 2023 | 338 | 2023 |
| First-in-human phase I study of pictilisib (GDC-0941), a potent pan–class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors D Sarker, JE Ang, R Baird, R Kristeleit, K Shah, V Moreno, PA Clarke, ... Clinical cancer research 21 (1), 77-86, 2015 | 331 | 2015 |
| Homologous recombination deficiency and ovarian cancer JA Ledermann, Y Drew, RS Kristeleit European journal of cancer 60, 49-58, 2016 | 265 | 2016 |
| Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated … AM Oza, AV Tinker, A Oaknin, R Shapira-Frommer, IA McNeish, ... Gynecologic oncology 147 (2), 267-275, 2017 | 261 | 2017 |
| A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors R Kristeleit, GI Shapiro, HA Burris, AM Oza, P LoRusso, MR Patel, ... Clinical Cancer Research 23 (15), 4095-4106, 2017 | 252 | 2017 |
| Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label … E Pujade-Lauraine, K Fujiwara, JA Ledermann, AM Oza, R Kristeleit, ... The Lancet Oncology 22 (7), 1034-1046, 2021 | 247 | 2021 |
| PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions GE Konecny, RS Kristeleit British journal of cancer 115 (10), 1157-1173, 2016 | 242 | 2016 |
| Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient … A Oaknin, L Gilbert, AV Tinker, J Brown, C Mathews, J Press, R Sabatier, ... Journal for immunotherapy of cancer 10 (1), 2022 | 229 | 2022 |
| A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45) BJ Monk, C Parkinson, MC Lim, DM O'malley, A Oaknin, MK Wilson, ... Journal of Clinical Oncology 40 (34), 3952-3964, 2022 | 202 | 2022 |
| Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ... Nature reviews Clinical oncology 8 (5), 302-306, 2011 | 148 | 2011 |
| Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2) EM Swisher, TT Kwan, AM Oza, AV Tinker, I Ray-Coquard, A Oaknin, ... Nature communications 12 (1), 2487, 2021 | 145 | 2021 |
| Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with … JS de Bono, R Kristeleit, A Tolcher, P Fong, S Pacey, V Karavasilis, ... Clinical Cancer Research 14 (20), 6663-6673, 2008 | 137 | 2008 |
| A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with … B Venugopal, R Baird, RS Kristeleit, R Plummer, R Cowan, A Stewart, ... Clinical Cancer Research 19 (15), 4262-4272, 2013 | 132 | 2013 |
| Detection of circulating tumour cell clusters in human glioblastoma I Krol, F Castro-Giner, M Maurer, S Gkountela, BM Szczerba, R Scherrer, ... British journal of cancer 119 (4), 487-491, 2018 | 126 | 2018 |
| Optimal treatment for relapsing ovarian cancer JA Ledermann, RS Kristeleit Annals of oncology 21, vii218-vii222, 2010 | 122 | 2010 |
| An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M … A Hollebecque, T Meyer, KN Moore, JPH Machiels, J De Greve, ... Journal of Clinical Oncology 35 (15_suppl), 5504-5504, 2017 | 120 | 2017 |
| Histone modification enzymes: novel targets for cancer drugs R Kristeleit, L Stimson, P Workman, W Aherne Expert opinion on emerging drugs 9 (1), 135-154, 2004 | 115 | 2004 |
